Top entities: Black Diamond Therapeutics, Julia Rotow, Sergey Yurasov, United States — Food and Drug Administration, American Society of Clinical Oncology.

What category does this event fall under?

Business — classified as clinical trial results.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business clinical trial results

Black Diamond Therapeutics' Silevertinib Phase 2 Success

Q: When did this event occur?

First reported May 21, 2026; last updated May 21, 2026.

Q: What is the market impact?

General. The positive Phase 2 results for Silevertinib are expected to significantly boost the stock price of Black Diamond Therapeutics, as the drug shows potential to address an unmet medical need in NSCLC.

Analysis based on 6 articles · First reported May 21, 2026 · Last updated May 21, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The positive Phase 2 results for Silevertinib are expected to significantly boost the stock price of Black Diamond Therapeutics, as the drug shows potential to address an unmet medical need in NSCLC. This development could also attract further investment into the biotechnology and pharmaceutical sectors, particularly for companies focused on oncology.

Biotechnology Pharmaceuticals

Event Summary

Black Diamond Therapeutics announced positive Phase 2 trial results for its investigational drug, Silevertinib, in frontline non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations. The trial demonstrated a preliminary median Progression-free Survival (mPFS) of 15.2 months and robust CNS activity, with no patients developing de novo brain metastases. The Objective Response Rate (ORR) was 60% across a broad spectrum of EGFR-NCMs. Julia Rotow from the Dana–Farber Cancer Institute will present these data at the 2026 American Society of Clinical Oncology Annual Meeting. Black Diamond Therapeutics plans to meet with the United States — Food and Drug Administration to discuss the pivotal development plan for Silevertinib, which is also being investigated for glioblastoma multiforme (GBM).

Entities Involved

stock

Black Diamond Therapeutics

Black Diamond Therapeutics announced positive Phase 2 trial results for Silevertinib, which is expected to significantly boost its stock price and market position in oncology.

Importance 100.0 Sentiment 75.0

per

Julia Rotow

Julia Rotow, Clinical Director at the Dana–Farber Cancer Institute, will present the positive Silevertinib data at the ASCO Annual Meeting, lending credibility to the findings.

Importance 40.0 Sentiment 50.0

per

Sergey Yurasov

Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics, expressed optimism about Silevertinib's potential to be a practice-changing therapy.

Importance 30.0 Sentiment 50.0

govactor

United States — Food and Drug Administration

Importance 0.0 Sentiment 0.0

ngo

American Society of Clinical Oncology

Importance 0 Sentiment 0

Relationships

United States — Food and Drug Administration related ↔ American Society of Clinical Oncology

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard